Join us at Virtual ASCO May 29 to May 31 to learn more about Invivoscribe’s new products and assay offerings!
LymphoQuant® Internal Control
Minimal Residual Disease (MRD) is being increasingly recognized as a biomarker and potential surrogate endpoint for a number of hematologic malignancies. We at Invivoscribe are excited to share details about LymphoQuant® for use with our LymphoTrack® assays to assess sample quality, qualify sensitivities, and estimate disease burden.
LymphoTrack® Low Positive Control
The LymphoTrack® Low Positive Control along with the LymphoQuant® and LymphoTrack® MRD bioinformatics software aids in tracking of MRD in longitudinal studies.
Stop splitting primary samples! You no longer have to split patient specimens as Invivoscribe will be able to offer combined flow cytometry and NGS-based biomarker testing in the near future.
Date: May 29 – May 31, 2020
If you would like to arrange a discussion, contact us at firstname.lastname@example.org.